Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

This protocol summary has been updated following Protocol Amendment 4 changes to study
objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022
(NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy
(HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)
separately.

Inclusion Criteria:

- Subjects who the investigator believes will comply with the requirements of the
protocol.

- Written informed consent obtained from the subject.

- A male or female aged 70 years or older at the time of the first vaccination.

Exclusion Criteria:

- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine, or planned use during the
study period.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product.

- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting
from disease or immunosuppressive/cytotoxic therapy History of HZ.

- Previous vaccination against varicella or HZ.

- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccine. Additionally, consider allergic reactions to other material or equipment
related to study participation.

- Significant underlying illness that in the opinion of the investigator would be
expected to prevent completion of the study.

- Receipt of immunoglobulins and/or any blood products within the 90 days preceding the
first dose of study vaccine or planned administration during the study period.

- Administration or planned administration of any other immunizations within 30 days
before the first or second study vaccination or scheduled within 30 days after study
vaccination. However, licensed non-replicating vaccines may be administered up to 8
days prior to each dose and/or at least 14 days after any dose of study vaccine.

- Any other condition that, in the opinion of the investigator, might interfere with the
evaluations required by the study.

- Acute disease and/or fever at the time of enrolment.

- Chronic administration of immunosuppressants or other immune-modifying drugs within
six months prior to the first vaccine dose.